General
Preferred name
valganciclovir
Synonyms
VALGANCICLOVIR HYDROCHLORIDE ()
Valganciclovir HCl ()
Valcyt ()
Valcyte ()
Valganciclovir (hydrochloride) ()
RS-079070-194 ()
RO-107-9070/194 ()
NSC-760349 ()
Valganciclovir (as hydrochloride) ()
RS-79070-194 ()
RO107-9070/194 ()
P&D ID
PD009449
CAS
175865-59-5
175865-60-8
Tags
available
prodrug
drug
Approved by
PMDA
FDA
First approval
2001
Drug indication
Virus infection
Anterior uveitis
Chronic lymphocytic leukemia
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Valganciclovir hydrochloride is an orally active antiviral agent. Valganciclovir hydrochloride can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir hydrochloride can be used for the research of Cytomegalovirus[1][2][3].
DESCRIPTION
Valcyte® contains valganciclovir hydrochloride (PubChem CID 110632). This is a prodrug of ganciclovir (PubChem CID 3454). The INN document for this drug specifies that there is a chiral centre at (position t8) and the INN-assigned compound consists of two epimers depending on the stereochemistry at this position. The structure shown here does not specify stereochemistry at this point and represents the mixture. This is represented by the '?' in the InChI standard identifier on the 'Structure' tab.
(GtoPdb)
DESCRIPTION
Valganciclovir hydrochloride (Valganciclovir HCl) is a hydrochloride salt form of valganciclovir, a prodrug form of ganciclovir, a nucleoside analog of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, and viral replication.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
61
Molecular Weight
354.17
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
4
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
2
cLogP
-1.44
TPSA
171.37
Fraction CSP3
0.57
Chiral centers
2.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CMV
Antiviral
Pathway
Anti-infection
Immunology/Inflammation
Therapeutic Class
Antiviral Agents
Source data
